Fig. 1

The modified GZT treatment inhibits tumor tumorigenicity and proliferation in vivo. A Representative xenograft tumors in the Model, Lower Dose and Higher Dose groups. B Tumor volume growth curve. C Tumor weight growth curve. D HE staining to observe histopathological changes (200 × , scale bar: 100 μm). E IHC staining was employed to measure GSDMD expression (magnification: 200 × , scale bar: 50 μm). F IHC staining for Ki67 (200 × , scale bar: 100 μm). G The modified GZT treatment inhibits the expression of tumor progress-related proteins. ^**P < 0.01 vs. Model group; ^##P < 0.01 vs. Lower Dose group